Science and Innovation Panel

The Science and Innovation Panel (SIP) provides the Governing Board with advice on matters relevant to IHI’s research and innovation activities.

 

The Science and Innovation Panel (SIP) was set up to gain input from a wider range of health and research stakeholders much earlier in the call topic design process. As such, the SIP is tasked with providing the Governing Board with science-based advice on a range of matters, including:

  • IHI’s draft work programmes, and in particular the scientific priorities and draft call topics;
  • updates to the Strategic Research and Innovation Agenda (SRIA);
  • scientific achievements of projects funded by IHI;
  • the planning of additional activities carried out by the industry partners;
  • the set-up of advisory groups focused on specific scientific priorities;
  • synergies with other Horizon Europe activities, including other European partnerships, as well as other EU and national programmes.

 

Membership

Anna Chioti and Ralf Herold
Anna Chioti (Chairperson) and Ralf Herold (Vice-Chairperson)

The current list of members can be found under the Members tab. The Chair of the SIP is Anna Chioti, and the Vice-Chair is Ralf Herold. They were elected in 2022 and their mandate lasts for three years. The composition of the SIP is set out in the legislation creating IHI and includes the following permanent panellists:

  • two representatives of the European Commission;
  • four representatives of the IHI industry partners;
  • two representatives of the States Representatives Group (SRG);
  • four representatives of the scientific community;
  • up to six other permanent panellists, representing the wider healthcare community, including the public sector, regulatory bodies, patients and end-users in general.

The European Commission, industry partners and SRG nominate their own representatives, while the representatives of the scientific and wider healthcare communities were appointed by the IHI Governing Board following a call for expressions of interest held at the beginning of 2022. When selecting representatives, the board focused on applicants’ expertise and experience and the recommendations of the States Representatives Group, while also ensuring the panel is balanced in terms of subject areas and stakeholder groups, geographical coverage, and gender.

In line with the IHI legislation, the Chair of the SIP was appointed from among the four representatives of the scientific community, and is invited to attend IHI Governing Board meetings where relevant.

 

Ad-hoc panellists

The SIP panellists from the European Commission, industry partners and SRG may invite ad-hoc panellists with key scientific or technical expertise to discuss specific subjects with the SIP.

 

Representatives of the scientific community

  • Mario Campone - Director General of the Institut de Cancérologie de l’Ouest (ICO); Professor at the Faculty of Medicine at the University of Angers / Oncologist at the Department of Medical Oncology (ICO) (France) 
  • Anna Chioti (Chair) - Head of Division Pharmacy and Medicines, Luxembourg Health Directorate - Direction de la santé (Luxemburg)
  • Jiri Mekyska - Head of the Brain Diseases Analysis Laboratory, Brno University of Technology (Czech Republic)
  • Maroeska Mariet Rovers - Professor of evidence-based surgery & Director of Health Innovation Netherlands (The Netherlands)

Representatives of the wider healthcare community, including the public sector, regulatory bodies, patients and end-users in general

  • Katariina Gehrmann - Head of Digital and Innovation services, Department of Children and Adolescents, HUS Helsinki (Finland)
  • Ralf Herold (Vice-Chair) - Senior Scientific Officer, Task Force Regulatory Science and Innovation, European Medicines Agency (The Netherlands)
  • Eva Hummers - Family physician in Department of General Practice, Göttingen University Medical Centre (Germany)
  • Peter Kapitein - CEO and Patient Advocate, Inspire2Life (The Netherlands)
  • Annika Tibell - Director, Research, Development, Education and Innovation, Karolinska University Hospital, Stockholm (Sweden)
  • Claudia Wild - Director & CEO, HTA Austria - Austrian Institute for Health Technology Assessment (AIHTA) GmbH (Austria)

Representatives of the European Commission

  • Arjon van Hengel - Deputy Head of Unit for Health Innovations & Ecosystems, Directorate-General for Research and Innovation
  • Ceri Thompson - Deputy Head of Unit for eHealth, Well-being and Ageing, Directorate-General for Communications Networks, Content and Technology

Representatives of the IHI industry partners

  • Sibilia Quilici (representing EuropaBio and Vaccines Europe) - Executive Director, Vaccines Europe
  • Bernd Stowasser (representing EFPIA) - Head of Sanofi Partnering Germany; Global Head of Sanofi Public Private Partnerships; Alliance Management Member of the EFPIA Research & Innovation Strategy (RIS) Group and Chair of the RIS Core Group
  • Nathalie Virag (representing Medtech Europe) - Responsible for the Strategic Partnership Program at Medtronic Corporate Science & Technology; member of the EIT (European Institute of Innovation and Technology) Health consortium supervisory board
  • Joanna Wills (representing COCIR) - Research Manager Northern Europe, GE Healthcare; Co-chair, COCIR Research & Innovation Panel

Representatives of the States Representatives Group (SRG)


Key documents

Details of how the Science and Innovation Panel works are set out in the SIP rules of procedure.

Agendas of SIP meetings